BofA Securities analyst Alec Stranahan maintains $Perspective Therapeutics (CATX.US)$ with a hold rating, and maintains the target price at $6.
According to TipRanks data, the analyst has a success rate of 51.2% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Perspective Therapeutics (CATX.US)$'s main analysts recently are as follows:
Perspective Therapeutics recently presented data for VMT-alpha-NET, which did not meet the expected overall response rate (ORR) when compared to industry benchmarks. There remains an opportunity for Perspective to achieve improved responses with higher dosage levels, though further data is not anticipated until late-2025 pending regulatory advancements. Additionally, initial findings for VMT01 in melanoma indicated kidney accumulation issues that could restrict dose escalation, potentially impacting the stock until further combination studies provide additional data.
Initial data from Cohort 1 and Cohort 2 of VMT-a-NET's phase I/IIa study indicate encouraging signals but underscore the need for patience in dose optimization. There appears to be a path to potential commercialization from Perspective's leading specific chelator across its pipeline and platform.
Yesterday's selloff in Perspective Therapeutics was seen as an overreaction to the early data from the dose escalation phase of the VMT-alpha-NET program, which showed clinical activity correlating with dose intensity and a clear safety profile that supports further dose escalation. This situation presents a buying opportunity, particularly with Perspective trading near cash levels.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Alec Stranahan維持$Perspective Therapeutics (CATX.US)$持有評級，維持目標價6美元。
根據TipRanks數據顯示，該分析師近一年總勝率為51.2%，總平均回報率為-2.7%。
此外，綜合報道，$Perspective Therapeutics (CATX.US)$近期主要分析師觀點如下：
Perspective Therapeutics最近公佈了VMT-Alpha-Net的數據，與行業基準相比，該數據未達到預期的總體響應率（ORR）。Perspective仍有機會通過更高的劑量水平改善反應，儘管預計要到2025年底才能獲得更多數據，等待監管方面的進展。此外，黑色素瘤中 VMT01 的初步發現表明存在腎臟積累問題，這可能會限制劑量增加，在進一步的組合研究提供更多數據之前，可能會對種群產生影響。
來自VMT-a-Net的I/IIa期研究隊列1和隊列2的初步數據顯示出令人鼓舞的信號，但突顯了在劑量優化方面需要耐心。Perspective領先的特定螯合劑在其產品線和平台上似乎有一條潛在的商業化之路。
Perspective Therapeutics昨天的拋售被視爲對VMT-Alpha-Net計劃劑量遞增階段的早期數據的過度反應，該數據顯示臨床活動與劑量強度相關，並且有明確的安全特徵支持劑量進一步增加。這種情況提供了買入機會，尤其是在Perspective交易接近現金水平的情況下。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
